

## Synthesis and in Vitro Evaluation of $^{18}\text{F}$ - and $^{19}\text{F}$ -Labeled Insulin: A New Radiotracer for PET-based Molecular Imaging Studies

Katharina J. Guenther,<sup>†</sup> Sabesan Yoganathan,<sup>†</sup> Robert Garofalo,<sup>‡</sup> Thomas Kawabata,<sup>‡</sup> Thomas Strack,<sup>‡</sup> Renée Labiris,<sup>§</sup> Myrna Dolovich,<sup>§</sup> Raman Chirakal,<sup>||</sup> and John F. Valliant<sup>\*†</sup>

Departments of Chemistry and Medical Physics & Applied Radiation Sciences, McMaster University, 1280 Main St. West, Hamilton, ON, Canada L8S 4M1, Pfizer Inc., 235 East 42nd Street 3/58, New York, New York 10017, Department of Medicine, McMaster University, 1200 Main St. West, Hamilton, ON, Canada L8M 3Z5, and Department of Radiology, Hamilton Health Sciences, 1200 Main St. West, Hamilton, ON, Canada L8M 3Z5

Received September 20, 2005

A new and regioselective strategy was developed for the preparation of fluorine-18-labeled insulin as a novel positron emission tomography (PET) tracer. [ $^{18}\text{F}$ ]-4-Fluorobenzoic acid (4- $^{18}\text{F}$ BFA), which was produced in  $83 \pm 8\%$  yield ( $n = 10$ ), through the use of succinimidyl [ $^{18}\text{F}$ ]-4-fluorobenzoate (4- $^{18}\text{F}$ FSB), was conjugated through a short spacer (6-aminohexanoic acid, AHx) to the PheB1 residue of a protected form of insulin.  $^{18}\text{F}$ B-AHx-insulin (**8b**) was repeatedly prepared in practical quantities (10–20 mCi, 370–740 MBq) in good radiochemical yield ( $9 \pm 5\%$ ,  $n = 9$ ) and in a specific activity of 7.8 mCi/ $\mu\text{mol}$ . The final product was characterized by comparing the radioHPLC and radioTLC of **8b** with that of the  $^{19}\text{F}$ -analogue ( $^{19}\text{F}$ B-AHx-insulin, **8a**) and by analyzing a carrier-added synthesis by mass spectrometry. Dithiothreitol and endoproteinase Glu-C digestion experiments on **8a** confirmed that the prosthetic group was in fact conjugated to the PheB1 residue. An insulin receptor (IR) phosphorylation assay using CHO-hIR cells overexpressing recombinant human insulin receptors indicated no statistical difference in the extent of autophosphorylation stimulated by **8a** as compared to that for human insulin ( $\text{EC}_{50}$  values of 0.82 nM and 1.0 nM, respectively). The stimulation of 2-deoxyglucose uptake in 3T3-L1 mouse adipocytes utilizing **8a** versus unmodified human insulin gave similar  $\text{EC}_{50}$  values of 0.68 nM and 0.41 nM, respectively. The  $\text{IC}_{50}$  values for **8a** versus native insulin for the displacement of  $^{125}\text{I}$ -insulin from HEK-293 cells were also the same within experimental error (2.6 nM for **8a** versus 2.4 nM for unmodified human insulin). These results support the use of the  $^{18}\text{F}$ -insulin analogue as a PET tracer for imaging the distribution of insulin in vivo.

### Introduction

The availability of dedicated scanners for imaging small animals is revolutionizing the drug discovery process and the study of biochemical processes.<sup>1,2</sup> Radioimaging is particularly suited for these studies because its sensitivity provides the opportunity to directly visualize the distribution and/or metabolism of specific compounds in living subjects noninvasively. This allows compounds to be studied in a more realistic environment compared to traditional methods, and it also allows longitudinal studies to be performed in the same animals, thereby avoiding subject-to-subject variability.<sup>2</sup> An advantage of using radioimaging over other molecular imaging methods, such as optical imaging, is that the radiotracers can be used for human studies and are not limited to experiments in small animals.

The two main radioimaging modalities are single photon emission computed tomography (SPECT) and positron emission computed tomography (PET). To employ these techniques to evaluate the distribution of drug candidates requires the synthesis and characterization of radiolabeled versions of the compounds under study. Not only must a method be developed to produce the tracer in good yield and purity but nonradioactive analogues must also be prepared and fully characterized. The “cold” compounds are needed to evaluate the impact of introducing the label on the biochemistry of the substrate, which is typically

done using in vitro assays. They are also needed as well characterized reference standards for the radiolabeled analogues.

Human insulin is a polypeptide-based hormone involved in the regulation of energy metabolite homeostasis.<sup>3</sup> Specifically, the secretion of insulin in response to high blood glucose levels stimulates the storage of metabolites as glycogen, lipids, and protein for future use when exogenous nutrients are not available.<sup>3</sup> Decreased insulin secretion alone or in combination with peripheral tissue resistance to insulin action leads to hyperglycemia and lipidemia both of which contribute to significantly greater cardiovascular morbidity and mortality in affected individuals.<sup>4</sup> Thus, ameliorating insulin resistance and increasing insulin levels appropriately to restore normal glucose and lipid levels are cornerstones of therapeutic strategies and have resulted in significant improvements in patient's health and quality of life.<sup>5,6</sup> It should also be noted that abnormal increases in insulin utilization are associated with a number of diseases, including diabetes, obesity, hypertension,<sup>4</sup> heart failure,<sup>7</sup> neurodegenerative diseases,<sup>8</sup> and cancer.<sup>9</sup>

A number of radiolabeled analogues of insulin have been reported as tracers for studying the biochemistry of the hormone and its role in disease progression and for evaluating different insulin delivery strategies.  $^{125}\text{I}$ -Labeled insulin, in which the isotope is bound to the aromatic ring of A14 tyrosine, is perhaps the best-known radiolabeled insulin derivative, but it is used solely for in vitro studies.<sup>10–14</sup> There are few reports of the synthesis of radiolabeled insulin analogues for in vivo molecular imaging studies using PET. Potential limitations of the studies that have been reported (which involved labeling insulin with  $^{18}\text{F}$ <sup>15,16</sup> and  $^{124}\text{I}$ <sup>17,18</sup>) include products that are of questionable


\* To whom correspondence should be addressed. Tel: (905) 525-9140, ext 22840. Fax: (905) 522-2509. E-mail: valliant@mcmaster.ca.

<sup>†</sup> Departments of Chemistry and Medical Physics & Applied Radiation Sciences, McMaster University.

<sup>‡</sup> Pfizer Inc.

<sup>§</sup> Department of Medicine, McMaster University.

<sup>||</sup> Hamilton Health Sciences.

**Scheme 1.** Preparation of B<sup>1</sup>-(4-Fluorobenzoyl)insulin,  $^{19}\text{F}$ FB-insulin (**4**)

stability, a lack of chemical and biological characterization data, and/or low overall production yields.

Herein a new method for the preparation of  $^{18}\text{F}$ -labeled insulin is described. The reported approach overcomes several of the limitations of existing strategies and is accompanied by detailed chemical and in vitro characterization of the nonradioactive (i.e.  $^{19}\text{F}$ ) analogue. The product of this research can be used to study the distribution and, indirectly, the biochemistry of insulin in vivo using PET.


## Results and Discussion

### Synthesis and Characterization of 4- $^{19}\text{F}$ FB-AHx-insulin.

The first objective was to prepare a  $^{19}\text{F}$ -labeled insulin analogue that would be used to determine if the addition of the label would have an impact on the biological activity of the hormone. The approach involved derivatizing the phenylalanine B1 (PheB1) amino acid of insulin with the *N*-hydroxysuccinimidyl active ester of 4- $^{19}\text{F}$ -fluorobenzoic acid (4- $^{19}\text{F}$ FSB). The amine of the PheB1 residue was deemed the most attractive site because this region of the hormone has been shown to not be involved in receptor binding.<sup>19–22</sup> Unfortunately, it has been well-documented that the reactivity of the PheB1 amino residue toward derivatization by electrophiles is less than that of the GlyA1 and LysB29 amino acids.<sup>23</sup> To circumvent this issue, Shai et al. and Baudy's et al. developed methods to selectively protect the GlyA1 and LysB29 amines with Boc groups,<sup>15,24</sup> thus providing a suitable precursor (DBI, **1**) for selective derivatization at PheB1.

Compound **1**, which was prepared in 70% yield, was reacted with succinimidyl 4-fluorobenzoate (4- $^{19}\text{F}$ FSB, **2a**) in the presence of triethylamine (TEA) (Scheme 1). The progress of the reaction between **1** and **2a** was followed by HPLC and it was apparent that conjugation was complete after 20 min. Compound **3** was purified by semipreparative HPLC, and the Boc groups were removed using a mixture of trifluoroacetic acid (TFA)/anisole according to the method described by Lundt et al.<sup>25</sup> Following purification by HPLC, the product (**4**) was lyophilized, yielding a white powder, which showed a single peak in the HPLC ( $t_R = 12.9$  min) and exhibited the expected mass-to-charge ratio in the electrospray mass spectrum (MS) (5928.0  $m/z$ ).

It was later discovered (vide infra) that the PheB1 residue does not react with 4- $^{18}\text{F}$ FSB when it is prepared in high specific activity. As a result, a short spacer group was attached to the PheB1 residue to increase the reactivity of the amine and to extend the site of conjugation away from the globular structure of insulin. The spacer chain used in this study was 6-amino-hexanoic acid (AHx). The amine was protected with an Fmoc group to allow for orthogonal deprotection with respect to the


**Scheme 2.** Preparation of B<sup>1</sup>-([4-Fluorobenzoyl]-6-amino-hexanoyl)insulin, FB-AHx-insulin (**8a**, **8b**)

Boc groups on the hormone, while the acid was converted to the active ester to facilitate bioconjugation (Scheme 2). Reaction of **5** with DBI (**1**) was done in a 10:1 molar ratio and was complete in 30 min as shown by HPLC. The resulting conjugate, which was precipitated from solution by the addition of ether, was subsequently treated with 20% (v/v) piperidine in DMF buffer to remove the Fmoc group. The reaction mixture was subsequently passed through a size-exclusion column as a means of removing dibenzofulvene and related derivatives using 100 mM  $\text{NH}_4\text{HCO}_3$  as the eluent. The purity of the free amine **6** was confirmed by HPLC and the electrospray MS, which showed the expected molecular ion at an  $m/z$  value of 6121.4.

Derivatization of **6** with 4- $^{19}\text{F}$ FSB was accomplished by adding **2a** to the substrate in DMSO-containing TEA. The reaction was followed by HPLC and the consumption of the amine was completed in 20 min, whereby the MS of **7a** showed a  $m/z$  value of 6243.4, which is consistent with the addition of a single FSB group. The Boc protecting groups were subsequently removed by treatment of **7a** with TFA in the presence of 5% anisole,<sup>25</sup> and the product was isolated by preparative HPLC. After lyophilization, the resulting precipitate was desalted using either dialysis against 100 mM  $\text{NH}_4\text{HCO}_3$  or size exclusion chromatography using 100 mM  $\text{NH}_4\text{HCO}_3$  as the eluent. The overall yield of synthesis was approximately 15% and the purity of **8a** was greater than 95% by RP-HPLC.

Liquid chromatography mass spectrometry (LCMS) (electrospray) analysis of **8a** showed a single peak in the HPLC at 6.56 min (Figure 1a), which resulted in three sets of peaks in the mass spectrum at  $m/z$  values of 1209.9, 1512.1, and 2015.4 (calcd 1209.6, 1511.7, and 2015.3, respectively) (Figure 1b). These three sets of peaks correspond to  $^{19}\text{F}$ FB-AHx-insulin (**8a**) bearing +5, +4, and +3 charges, respectively. Additional peaks in the mass spectrum appeared that correlate with TFA adducts of the parent ion. The MALDI-TOF mass spectrum showed the parent ion at a  $m/z$  value of 6043.8, which is consistent with the calculated mass of **8a**.


The  $^{19}\text{F}$  NMR spectrum of **8a** (Figure 2) shows a single multiplet containing broad peaks centered at  $-109.60$  ppm. The  $^3J_{\text{FH}}$  and  $^4J_{\text{FH}}$  couplings were 8.9 and 5.6 Hz, respectively. As a reference, the  $^{19}\text{F}$  NMR spectra of [ $^{19}\text{F}$ ]-4-fluorobenzoic acid (4- $^{19}\text{F}$ FBA) and **2a** were acquired, which each show single



**Figure 1.** (a) RP-HPLC chromatogram of  $^{19}\text{F}$ -AHx-insulin (**8a**). (b) ES(+) MS of FB-AHx-insulin (**8a**) from LCMS analysis scanned from 1100 to 2200  $m/z$ .

multiplets (nonets) centered at  $-106.67$  and  $-101.42$  ppm, respectively. The  $^3J_{\text{FH}}$  and  $^4J_{\text{FH}}$  coupling constants for 4- $^{19}\text{F}$ BFA and compound **2a** are identical to that in **8a**. The broad lines in the  $^{19}\text{F}$  NMR spectrum of **8a** and the increased complexity of the observed multiplet are likely the result of the existence of multiple conformations of the hormone derivative, which is consistent with the NMR studies on insulin reported by Weiss et al.<sup>26</sup>

To confirm the site of derivatization, compound **8a** was initially treated with dithiothreitol to disrupt the interchain disulfide bonds.<sup>27</sup> LCMS analysis of the sample (Table 1) showed a peak at 88.36 min with an  $m/z$  value of 1190.1, which corresponds to the molecular ion of the unmodified A-chain. A peak at 104.99 min with an  $m/z$  value of 1222.0 corresponds to the B-chain plus the FB-AHx pendant group attached ( $[\text{M} + \text{H}^+]$ ).



**Figure 2.**  $^{19}\text{F}$  NMR spectra (DMSO- $d_6$ , 470.6 MHz) of 4-fluorobenzoic acid (left),  $^{19}\text{F}$ SB (**2a**) (middle), and  $^{19}\text{F}$ FB-AHx-insulin (**8a**) (right).

**Table 1.** LCMS (ES+) Studies of  $^{19}\text{F}$ FB-AHx-insulin (**8a**) Fragments after Dithiothreitol Treatment

HPLC $t_R^a$	MS found (calcd)	molecular ion	fragment
88.36	1190.1 (1192.9)	$[\text{M} + 2\text{H}^+]/2$	A-chain
104.99	1222.0 (1222.8)	$[\text{M} + 3\text{H}^+]/3$	FB-AHx-B-chain

<sup>a</sup> HPLC column and conditions:  $\text{C}_{18}$  Beckmann Ultrasphere ( $150 \times 4.6$  mm, porosity  $5 \mu\text{m}$ ); mobile phase A,  $\text{H}_2\text{O}$  with 0.05% TFA; mobile phase B, 90/10 (v/v)  $\text{H}_2\text{O}/\text{CH}_3\text{CN}$  with 0.05% TFA; gradient, 99:1 (A/B) for 10 min, 99:1 (A/B) to 11:89 (A/B) for 140 min, 11:89 (A/B) to 99:1 (A/B) for 3 min, 99:1 (A/B) for 17 min; flow rate = 0.1 mL/min.

**Table 2.** LCMS (ES+) Studies of  $^{19}\text{F}$ FB-AHx-insulin (**8a**) Fragments after Endoproteinase Glu-C Digestion

HPLC $t_R^a$	MS found (calcd)	molecular ion	fragment
65.41	417.5 (417.5)	$[\text{M} + \text{H}^+]$	GIVE (A-chain)
78.99	1116.6 (1117.3)	$[\text{M} + \text{H}^+]$	RGFFYTPKT (B-chain)
103.87	1145.1 (1146.3)	$[2\text{M} + 3\text{H}^+]/3$	FB-AHx-FVNQHLGSHLVE (B-chain)

<sup>a</sup> HPLC column and conditions:  $\text{C}_{18}$  Beckmann Ultrasphere ( $150 \times 4.6$  mm, porosity  $5 \mu\text{m}$ ); mobile phase A,  $\text{H}_2\text{O}$  with 0.05% TFA; mobile phase B, 90/10 (v/v)  $\text{H}_2\text{O}/\text{CH}_3\text{CN}$  with 0.05% TFA; gradient, 99:1 (A/B) for 10 min, 99:1 (A/B) to 11:89 (A/B) for 140 min, 11:89 (A/B) to 99:1 (A/B) for 3 min, 99:1 (A/B) for 17 min; flow rate = 0.1 mL/min.

The sample was subsequently treated with endoproteinase Glu-C, an enzyme that facilitates cleavage of peptides at the carbonyl side of glutamic acid residues.<sup>27</sup> As demonstrated in Table 2, the peak at 65.41 min resulted in a  $m/z$  of 417.5, which is consistent with the  $[\text{M} + \text{H}^+]$  fragment: GIVE from the A-chain, confirming that derivatization did not occur at the GlyA1 residue. The peak at 78.99 min exhibited a  $m/z$  value of 1116.6, which matches the fragment RGFFYTPKT ( $[\text{M} + \text{H}^+]$ ) from the B-chain. There was no peak that corresponded to the attachment of the pendant group  $^{19}\text{F}$ FB-AHx to the lysine residue of RGFFYTPKT from the B-chain. Interestingly, the fragment FB-AHx-FVNQHLGSHLVE was also not observed; however, the HPLC peak at 103.87 min gave rise to two  $m/z$  values of 859.1 and 1145.1. These correspond to a proton-bound dimer ( $[2\text{M} + 3\text{H}^+]/3$ ) of the fragment FB-AHx-FVNQHL-


CGSHLVE, which is consistent with the prosthetic group being attached to the PheB1 residue and not the GlyA1 or LysB29 sites.

**In Vitro Screening of 8a.** The bioactivity of **8a** was determined in vitro in direct comparison to human insulin using a number of assays. The first assay was an intact cell insulin receptor autophosphorylation assay in CHO cells, which over-express recombinant human insulin receptors (CHO-hIR). There was no statistically significant difference observed in the extent of autophosphorylation induced by FB-AHx-insulin as compared to unmodified human insulin (Figure 3). The calculated  $\text{EC}_{50}$  for the autophosphorylation was 0.82 nM for FB-AHx-insulin and 1.0 nM for unmodified human insulin.


The second assay was performed to determine if compound **8a** could stimulate glucose uptake. The extent of 2-deoxyglucose uptake in 3T3-L1 (mouse) adipocyte cells induced by **8a** was not significantly different from that induced by unmodified human insulin (Figure 4). The calculated  $\text{EC}_{50}$  values were 0.41 nM for human insulin and 0.68 nM for **8a**.

The ability of **8a** to bind to the insulin receptor was determined using a displacement assay involving recombinant  $^{125}\text{I}$ -insulin and HEK-293 cells expressing the recombinant human insulin receptor. The displacement curves for human insulin and  $^{19}\text{F}$ FB-AHx-insulin (**8a**) were, within experimental error, equivalent (Figure 4), with 50% displacement achieved at concentrations of 2.6 nM for **8a** and 2.4 nM for unmodified insulin, respectively.

**Radiochemistry.**  $^{18}\text{F}$ FB-AHx-insulin (**8b**) was synthesized in five steps from compound **9** (Schemes 2 and 3), which was prepared following literature procedures.<sup>28</sup>  $^{18}\text{F}[\text{F}^-]$  was added to **9** and Kryptofix222 (4,7,13,16,21,24-hexaoxa-1,10-diazabicyclo[8.8.8]hexacosane) in anhydrous  $\text{CH}_3\text{CN}$  and the mixture heated to  $130^\circ\text{C}$  for 10 min (Scheme 3). Compound **10** was purified using a silica cartridge and was obtained in  $76 \pm 9\%$  radiochemical yield ( $n = 10$ , decay-corrected). TFA was added to compound **10**, cooled in an ice bath, to remove the pentamethylbenzyl-protecting group. After 5 min, the residual TFA was evaporated, which resulted in a significant loss of activity (between 50% and 80%).




**Figure 3.** Comparisons of Aventis (human) insulin and  $^{19}\text{F}$ B-AHx-insulin (**8a**): insulin receptor autophosphorylation ELISA with 50 mL of CHO-hIR lysate/well (24-well plate);  $n = 3$  wells per treatment.



**Figure 4.** Comparisons of Aventis (human) insulin and  $^{19}\text{F}$ B-AHx-insulin (**8a**): insulin dose–response for 2-deoxyglucose uptake in 3T3-L1 adipocytes (left); displacement of bound  $^{125}\text{I}$ -insulin in HEK-293 cells expressing recombinant human insulin receptor (right).

**Scheme 3.** Preparation of Succinimidyl 4- $^{18}\text{F}$ -Fluorobenzoate (4- $^{18}\text{F}$ FSB,  $^{18}\text{F}$ -**2b**)



To determine the nature of the volatile species, a trapping experiment was performed where the TFA was removed by blowing  $\text{N}_2$  over the sample while passing the gas through a separate vial cooled to  $-5^\circ\text{C}$ . The radiochromatogram (HPLC) of the volatile compounds showed that the collected radioactive product was, as expected, compound **11**. The extent of sublimation, even under fairly mild evaporation conditions, was significant.

To alleviate the loss, it is possible to add  $\text{NMe}_4\text{OH}$  to the solution prior to the evaporation step.<sup>29</sup> We found this approach problematic in terms of the base's impact on the reproducibility in the subsequent step involving formation of the active ester. As an alternative approach, following acid deprotection, the resulting mixture was diluted with  $\text{H}_2\text{O}$  (5 mL) and passed through an activated  $\text{C}_{18}$  cartridge. The cartridge was washed with  $\text{H}_2\text{O}$  (5 mL) to remove any residual TFA and then dried for 1 min using a stream of nitrogen. Compound **11** was subsequently eluted from the cartridge using anhydrous  $\text{CH}_3\text{CN}$  (3 mL) in  $88 \pm 6\%$  yield ( $n = 10$ , decay-corrected), and it can be directly converted to the active ester **2b** without having to evaporate the solvent. This approach prevented loss due to sublimation and is easily automated.

To prepare the active ester (Scheme 3), *N*-hydroxysuccinimide and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride in anhydrous  $\text{CH}_3\text{CN}$  were added to the  $\text{CH}_3\text{CN}$  solution of **11**. The reaction was stirred at room temperature for 10 min and the product subsequently isolated by semipreparative HPLC in  $83 \pm 8\%$  yield ( $n = 10$ , decay-corrected). HPLC purification of **2b** was necessary to ensure reproducibility in the subsequent conjugation reaction.

Initially, attempts were made to conjugate **2b** to the PheB1 residue of diBoc-insulin **1**, on the basis of the successful synthesis of the nonradioactive analogue. However, formation of the bioconjugate was not observed. Varying the solvent (DMSO, DMF, PBS, or borate buffers), temperature (room temperature to  $50^\circ\text{C}$ ), and the amount of **1** (2–18 mg) had no effect on the reaction with the exception of increasing the amount of **11**, which formed as a result of hydrolysis of the active ester.

In contrast to the direct reaction of **2b** with **1**, successful conjugation with **6** was achieved in 20 min (Scheme 2). The product,  $^{18}\text{F}$ B-AHx-DBI (**7b**), was isolated from low molecular weight compounds using a size-exclusion cartridge in  $43 \pm 10\%$  yield ( $n = 9$ , decay-corrected). The last step involved the

removal of the Boc protecting groups by treating **7b** with neat TFA in the presence of anisole, which was followed by purification using a size-exclusion cartridge. Residual AHx-insulin in the sample can be removed by preparative HPLC (method B, see Experimental Procedures). However, because the effective specific activity was already 7.8 mCi/ $\mu\text{mol}$  and because our future imaging studies involve mixing the tracer with a large excess of insulin, further purification was deemed unnecessary. The HPLC retention times of the final product matched that of the  $^{19}\text{F}$  reference standard. Typically, 37–74 MBq (1–2 mCi) of  $\text{B}^1$ -([4- $^{18}\text{F}$ -fluorobenzoyl]-6-aminohexanoyl)-insulin (**8b**) was obtained in 180–200 min starting from a 2.78 GBq (75 mCi) of  $^{18}\text{F}$  [ $\text{F}^-$ ], giving a total yield, based on  $^{18}\text{F}^-$ , of  $9 \pm 5\%$  yield ( $n = 9$ , decay-corrected). This approach was also amenable to producing significant quantities of the product tracer. Higher production runs starting with 25.2 GBq (680 mCi) yielded 470 MBq (12.7 mCi) of **8b** (decay-corrected yield of 6%).

To further verify that  $^{18}\text{F}$ B-AHx-insulin (**8b**) was in fact the product, carrier-added experiments were performed by adding 0.1 mg of  $^{19}\text{F}^-$  to the Kryptofix solution prior to the addition of  $^{18}\text{F}^-$ . The radioactivity was allowed to decay to background and the reaction mixture characterized by MALDI-TOF mass spectrometry. A peak was observed at a  $m/z$  value of 6043.8, which is consistent with the mass spectrum of **8a** prepared from **2a**.

## Conclusion

A reproducible method for the preparation of a  $^{18}\text{F}$ -labeled analogue of insulin was developed. The  $^{19}\text{F}$  version was screened in a series of in vitro assays where it was indistinguishable from native insulin. These studies indicate that  $^{18}\text{F}$ B-AHx-insulin is a viable PET tracer for studying the distribution and biochemistry of insulin in vivo. The compound is currently being evaluated in a series of PET studies using both small and large animal models, which will be reported in due course.

## Experimental Procedures

**Materials and Instrumentation.** Chemicals were purchased from Aldrich Inc., NovaBiochem Inc., or Fluka Inc. and were used without further purification. Human insulin was obtained from Aventis Inc. Anhydrous  $\text{CH}_3\text{CN}$  (Aldrich, 99.8%), anhydrous DMSO (Aldrich, 99.9%), Kryptofix222 ( $\text{K}_{222}$ : 4,7,13,16,21,24-hexaoxa-1,10-diazabicyclo[8.8.8]hexacosane, Aldrich, 98%),  $\text{KHCO}_3$  (British Drug Houses, 99.5%), and [ $^{18}\text{O}$ ] $\text{H}_2\text{O}$  (Isotec, 98%  $^{18}\text{O}$ ) were used where indicated. Saline solution (0.9%, USP grade) was obtained from Baxter Inc. Dibasic sodium phosphate (J. T. Baker, USP grade) solution (0.9%) was prepared immediately prior to use using a sterile container and sterile  $\text{H}_2\text{O}$  designated for human use. Pentamethylbenzyl 4-( $N,N,N$ -trimethylammonium trifluoromethanesulfonate)benzoate (**9**) was synthesized following literature procedures.<sup>28</sup>

TLC was run on plates of silica gel 60-F<sub>254</sub> (Merck). Nonradioactive compounds were visualized by UV ( $\lambda = 254$  nm), while radioactive compounds were detected using a BioScan TLC analyzer. Chromatatron plates were made from a slurry of silica gel (60-PF<sub>254</sub>) containing gypsum (120 g) in deionized  $\text{H}_2\text{O}$  (230 mL) and dried for 24 h at 110 °C.

Size-exclusion chromatography (SEC) was run using Sephadex G-25 resin (Aldrich, Inc.), which was swollen in 100 mM  $\text{NH}_4\text{HCO}_3$  for 24 h prior to use. The void volume was determined by measuring the volume required to elute a 1 mL solution of Dextran Blue. SEC HiTrap desalting cartridges (GE Healthcare) were activated with 20 mL of 100 mM  $\text{NH}_4\text{HCO}_3$  (dropwise) immediately prior to use. Following use, the cartridges were washed with 20 mL of buffer, 20 mL of  $\text{H}_2\text{O}$ , and 20 mL of 80/20 (v/v)  $\text{H}_2\text{O}/\text{EtOH}$ . Resins were stored in 80/20 (v/v)  $\text{H}_2\text{O}/\text{EtOH}$ . Activation

of silica cartridges (Waters) was completed immediately prior to use using  $\text{Et}_2\text{O}$  (10 mL), while RP C<sub>18</sub> cartridges (Waters) were activated with  $\text{EtOH}$  (10 mL) followed by  $\text{H}_2\text{O}$  (10 mL).

For nonradioactive materials, analytical and semipreparative HPLC experiments were performed using a Varian ProStar system, fitted with a 330 PDA multiwavelength detector, a 230 solvent delivery module, and a Beckmann Ultrasphere C<sub>18</sub> column (4.6  $\times$  150 mm, 300 Å-5  $\mu\text{m}$ ), or a semipreparative Microsorb Dynamax C<sub>18</sub> column (10  $\times$  250 mm, 300 Å-5  $\mu\text{m}$ ). The elution protocol (method A) consisted of a gradient over 20 min from 75/25 A/B (v/v) to 20/80 A/B which was followed by 10/90 A/B for 10 min (mobile phase A = 0.1% TFA in  $\text{H}_2\text{O}$ , mobile phase B = 0.1% TFA in  $\text{CH}_3\text{CN}$ ) with the flow rates set at 1.0 and 4.0 mL/min for analytical and semipreparative runs, respectively. The UV detector was set at  $\lambda = 254$  and 210 nm.

For preparative HPLC runs, a Varian ProStar preparative HPLC system, which consisted of a model 320 uniwavelength detector, a model 215 solvent delivery system, and a Microsorb Dynamax C<sub>18</sub> column (21.4  $\times$  250 mm, 300 Å-5  $\mu\text{m}$ ), was used. The elution protocol (method B) consisted of a gradient from 75/25 A/B (v/v) to 20/80 A/B over 20 min followed by 20/80 A/B (v/v) to 100% B over 5 min (mobile phase A = 0.1% TFA in  $\text{H}_2\text{O}$ , mobile phase B = 0.1% TFA in  $\text{CH}_3\text{CN}$ ) at a flow rate of 30 mL/min. The absorbance was monitored at  $\lambda = 254$  nm.

For the analysis of radioactive compounds, a Hewlett-Packard 1090 analytical system fitted with a diode array multiwavelength detector, a model PV5 solvent delivery system, a NaI detector connected to a Carroll and Ramsey Model 105S ratemeter, and a Beckmann Ultrasphere C<sub>18</sub> column (4.6  $\times$  150 mm, 300 Å-5  $\mu\text{m}$ ) were employed. The elution protocol (method C) consisted of a gradient over 20 min consisting of 75/25 A/B (v/v) to 20/80 A/B and then 10/90 A/B for 10 min (mobile phase A = 0.1% TFA in  $\text{H}_2\text{O}$ , mobile phase B = 0.1% TFA in  $\text{CH}_3\text{CN}$ ) at a flow rate of 1.0 mL/min. The absorbance was monitored at  $\lambda = 254$  nm.

For purification of radioactive materials, a Waters 6000A solvent delivery system fitted with Beckman UV detector (fixed wavelength at 280 nm) and a Bicon GM tube (SWG M B980C) attached to a Bicon ratemeter was employed. Using a semipreparative C<sub>18</sub> Vydac column (10  $\times$  250 mm, 300 Å-5  $\mu\text{m}$ ), the elution protocol (method D) was isocratic 50/50 A/B (v/v) (solvent A =  $\text{H}_2\text{O}$ ; solvent B =  $\text{CH}_3\text{CN}$ ) at a flow rate of 3.0 mL/min. The absorbance was monitored at  $\lambda = 254$  nm.

LCMS experiments were run on a Waters 2690 separations module, a model 996 photodiode array multiwavelength detector and a Micromass Quatro Ultima electrospray ionization instrument. For the digestion studies, a C<sub>18</sub> Beckmann Ultrasphere (150  $\times$  4.6 mm, porosity 5  $\mu\text{m}$ ) column was employed using a mobile phase of A:  $\text{H}_2\text{O}$  with 0.05% TFA and B: 90/10 (v/v)  $\text{H}_2\text{O}/\text{CH}_3\text{CN}$  with 0.05% TFA and a gradient of 99/1 A/B (v/v) for 10 min, 99/1 A/B to 11/89 A/B for 140 min, 11/89 A/B to 99/1 A/B for 3 min and 99/1 A/B for 17 min at a flow rate of 0.1 mL/min.

MALDI-TOF experiments were carried out on a Micromass TOF Spec2E instrument. Prior to each analysis, a calibration standard was run that consisted of a mixture of 1  $\mu\text{mol}/\mu\text{L}$  substance P, 2 pmol/ $\mu\text{L}$  renin substrate tetradecapeptide, 2 pmol/ $\mu\text{L}$  adrenocorticotrophic hormone fragment 18–39, and 10 pmol/ $\mu\text{L}$  cytochrome c. This was done in the positive ion reflection mode at 20 kV.

NMR spectra were predominately recorded using a Bruker Avance (AV 200 MHz) instrument and spectra were referenced to the residual proton peaks in deuterated solvents (DMSO-*d*<sub>6</sub>,  $\delta = 2.50$  ppm;  $\text{CD}_2\text{Cl}_2$ ,  $\delta = 5.32$  ppm;  $\text{CD}_3\text{OD}$ ,  $\delta = 3.30$  and 4.78 ppm) or TMS. Characterization of **8a** was completed using a Bruker AV Ultra Shield Plus (700 MHz) spectrometer at 37 °C.  $^{19}\text{F}$  NMR experiments were recorded using a Bruker Avance (DRX 500 MHz) instrument and the chemical shifts referenced to  $\text{CFCl}_3$ . Abbreviations of multiplicity: q = quartet, qu = quintet.

**Radiochemistry.** Radiosyntheses were performed in a shielded hot cell (7.5 cm lead) using remote manipulators for high level experiments (**Caution:**  $^{18}\text{F}$  is radioactive and should be handled in a licensed facility using the appropriate shielding). Specific radioactivity was determined as follows: the area of the absorbance

peak corresponding to the radiolabeled product was measured on the HPLC chromatogram and compared to a standard curve relating mass to absorbance.

**Radioisotope Production.** No-carrier-added  $^{18}\text{F}$ -fluoride was produced using a Siemens 11 MeV proton-only cyclotron (RDS 112) using an  $^{18}\text{O}(\text{p},\text{n})^{18}\text{F}$  reaction. The  $[\text{H}_2\text{O}]^{18}\text{O}$  was separated from  $^{18}\text{F}^-$  by passing the mixture through an anion exchange column (BioRad, AG 11 A8 resin, 50–500 mesh, converted to  $\text{HCO}_3^-$  form). The  $^{18}\text{F}^-$  was subsequently eluted from the column using of 95/5 (v/v)  $\text{CH}_3\text{CN}/\text{H}_2\text{O}$  (1 mL) solution containing 8 mg of  $\text{K}_{222}$  and 2 mg  $\text{KHCO}_3$  and collected in a 10-mL vial, and the solvent was evaporated at 130 °C. The residue was redissolved in anhydrous  $\text{CH}_3\text{CN}$  (0.5 mL) and evaporated to dryness. The drying procedure was repeated a second time before use.

**Synthetic Procedures. A<sup>1</sup>,B<sup>29</sup>-Di(*tert*-butyloxycarbonyl)insulin (DBI, **1**).** A modification of the literature procedure reported by Shai et al. was employed.<sup>15</sup> A solution of di-*tert*-butyl dicarbonate (0.188 g, 0.86 mmol), TEA (200  $\mu\text{L}$ ), and *N*-hydroxysuccinimide (0.207 g, 1.80 mmol) was stirred in DMSO (500  $\mu\text{L}$ ) for 1 h. The solution was subsequently added dropwise over 2 h (20 gauge needle, 1 drop every 30 s) via a 1-mL syringe to a rapidly stirring solution of human insulin (2.0 g, 0.344 mmol) dissolved in DMSO (40 mL) containing 5% TEA (v/v). The reaction mixture was allowed to stir for 1 h and subsequently divided equally among eight centrifuge vials, which contained 30 mL of cold  $\text{Et}_2\text{O}$ . Precipitation was induced through the addition of 5–8 mL  $\text{CH}_3\text{CN}$ . The solid was isolated by centrifugation (3200 rpm) at 5 °C. The residue was washed twice with 50/50 (v/v)  $\text{Et}_2\text{O}/\text{CH}_3\text{CN}$  and isolated by centrifugation. The solid was dissolved in a 75/25 (v/v)  $\text{H}_2\text{O}/\text{CH}_3\text{CN}$  containing 0.1% TFA and the desired product purified using preparative HPLC (method B). Fractions collected were concentrated by rotary evaporation (water bath at 30 °C) to remove the majority of the  $\text{CH}_3\text{CN}$  followed by lyophilization overnight, which yielded a white solid. The solid was subsequently desalted by SEC using a 100 mM  $\text{NH}_4\text{HCO}_3$  buffer as the eluent. Following lyophilization, compound **1** (1.49 g, 72%) was obtained as a colorless solid. Anal. HPLC (method A):  $t_{\text{R}} = 7.80$  min. MS  $m/z$  ES(+): found, 1202.4 [M + 5H<sup>+</sup>]/5, 1503.0 [M + 4H<sup>+</sup>]/4, 2004.0 [M + 3H<sup>+</sup>]/3; calcd, 1202.8, 1503.0, 2003.6, respectively.

**Succinimidyl 9-Fluorenylmethoxycarbonyl-6-aminohexanoate (5).** To a solution of 9-fluorenylmethoxycarbonyl-6-aminohexanoic acid (1.0 g, 2.83 mmol) in  $\text{CH}_3\text{CN}$  (500 mL) were added *N*-hydroxysuccinimide (0.411 g, 3.57 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.698 g, 3.57 mmol). The reaction was allowed to stir at room temperature for 2 h, at which time it was concentrated to dryness using a rotary evaporator. The residue was dissolved in  $\text{CH}_2\text{Cl}_2$  (25 mL) and extracted with  $\text{H}_2\text{O}$  (2  $\times$  20 mL). The organic layer was dried with  $\text{MgSO}_4$ , filtered, and then concentrated to dryness using a rotary evaporator. The residue was redissolved in  $\text{CH}_2\text{Cl}_2$  (1–2 mL) and purified using a chromatotron and a solvent gradient consisting of 100%  $\text{CH}_2\text{Cl}_2$  to 90/10 (v/v)  $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}$ . The product (0.83 g, 65%) was a colorless solid.  $R_f$  (DCM/MeOH 95/5, v/v): 0.78.  $\text{M}_p = 110\text{--}113$  °C.  $^1\text{H}$  NMR ( $\text{CD}_2\text{Cl}_2$ ):  $\delta$  7.78 (d, 2H,  $J = 7.5$  Hz); 7.62 (d, 2H,  $J = 7.4$  Hz); 7.44 (dd, 2H,  $J = 7.5, 7.4$  Hz); 7.32 (dd, 2H,  $J = 7.4, 7.4$  Hz); 4.98 (br s, 1H); 4.37 (d, 2H,  $J = 6.7$  Hz); 4.22 (t, 1H,  $J = 6.5$  Hz); 3.17 (d, 2H,  $J = 6.2$  Hz); 2.79 (s, 4H); 2.61 (t, 2H,  $J = 7.2$  Hz); 1.76 (qu, 2H); 1.53 (qu, 2H); 1.44 (m, 4H).  $^{13}\text{C}$  NMR ( $\text{CD}_2\text{Cl}_2$ ):  $\delta$  169.87, 169.24, 156.80, 144.77, 141.85, 128.16, 127.55, 125.64, 120.45, 66.83, 47.93, 41.15, 31.39, 29.89, 26.26, 26.19, 24.81. IR (KBr,  $\text{cm}^{-1}$ ):  $\nu$  3366.10 (N–H), 1725.87 (C=O), 1693.77 (C=O), 1528.69 (C=C). MS  $m/z$  ES(+): found, 451.3 [M + H<sup>+</sup>]; calcd, 451.5.

**A<sup>1</sup>,B<sup>29</sup>-Di(*tert*-butyloxycarbonyl)-B<sup>1</sup>-(6-aminohexanoyl)insulin (AHx-DBI, **6**).** A solution of DBI (**1**) (40.7 mg, 6.77  $\mu\text{mol}$ ) and **5** (30.5 mg, 67.7  $\mu\text{mol}$ ) in DMSO (400  $\mu\text{L}$ ) containing 5% TEA (v/v) was allowed to stir at room temperature for 30 min. The reaction mixture was transferred to a centrifuge vial containing cold  $\text{Et}_2\text{O}$  (2 mL) and precipitation induced by the addition of  $\text{CH}_3\text{CN}$  (1.5 mL). The resulting solid was isolated by centrifugation (3200 rpm) at 5 °C, washed twice with a 50/50 (v/v)  $\text{Et}_2\text{O}/\text{CH}_3\text{CN}$

solution, and reisolated by centrifugation. The residue was collected by filtration through a fritted funnel. Anal. HPLC (method A):  $t_{\text{R}} = 12.2$  min. MS  $m/z$  ES(+): found, 1586.8 [M + 4H<sup>+</sup>]/4, 2116.2 [M + 3H<sup>+</sup>]/3; calcd, 1586.9, 2115.5, respectively.

The precipitate was transferred to a vial and DMF (600  $\mu\text{L}$ ) containing 20% piperidine (v/v) added. The reaction was allowed to stir for 20 min, at which time the mixture was transferred to a centrifuge vial containing cold  $\text{Et}_2\text{O}$  (2 mL) and precipitation induced by the addition of  $\text{CH}_3\text{CN}$  (1.5 mL). Isolation of the solid followed the same procedure described above. The solid was dissolved in 75/25 (v/v)  $\text{H}_2\text{O}/\text{CH}_3\text{CN}$  containing 0.1% TFA and the desired product purified using preparative HPLC (method B). The collected fractions were concentrated by rotary evaporation (water bath at 30 °C) to remove the majority of the  $\text{CH}_3\text{CN}$  followed by lyophilization overnight, which yielded a white solid. The solid was subsequently desalted by SEC using a 100 mM  $\text{NH}_4\text{HCO}_3$  buffer as the eluent. Following lyophilization, compound **6** (29 mg, 69%) was obtained as a colorless solid. Anal. HPLC (method A):  $t_{\text{R}} = 8.91$  min. MS  $m/z$  ES(+): found, 1531.1 [M + 4H<sup>+</sup>]/4, 2041.7 [M + 3H<sup>+</sup>]/3; calcd, 1531.3, 2041.3, respectively.

**A<sup>1</sup>,B<sup>29</sup>-Di(*tert*-butyloxycarbonyl)-B<sup>1</sup>-(4-fluorobenzoyl)-6-aminohexanoyl)insulin ( $^{19}\text{F}$ B-AHx-DBI, **7**).** A solution of **6** (10.0 mg, 1.63  $\mu\text{mol}$ ) and succinimidyl 4-fluorobenzoate (**2a**) (3.87 mg, 16.3  $\mu\text{mol}$ ) in DMSO (100  $\mu\text{L}$ ) containing 5% TEA (v/v) was allowed to stir at room temperature for 20 min. The reaction mixture was transferred to a centrifuge vial containing cold  $\text{Et}_2\text{O}$  (1 mL), whereupon precipitation was induced by the addition of  $\text{CH}_3\text{CN}$  (0.5 mL). Isolation of the solid was accomplished by centrifugation at 5 °C (3200 rpm). Compound **6** was isolated by semipreparative HPLC (method A) which, after lyophilization, resulted in a colorless solid (5.7 mg, 56%). Anal. HPLC (method A):  $t_{\text{R}} = 11.4$  min. MS  $m/z$  ES(+): found, 1561.6 [M + 4H<sup>+</sup>]/4, 2082.7 [M + 3H<sup>+</sup>]/3; calcd, 1562.0, 2082.4, respectively.

**B<sup>1</sup>-(4-Fluorobenzoyl)-6-aminohexanoyl)insulin ( $^{19}\text{F}$ B-AHx-insulin, **8a**).** To a vial containing **7** (2.1 mg, 0.34  $\mu\text{mol}$ ) were added anisole (5  $\mu\text{L}$ , 46.0  $\mu\text{mol}$ ) and TFA (100  $\mu\text{L}$ ), and the reaction was allowed to stir at room temperature for 10 min. The reaction mixture was transferred to a centrifuge vial containing cold  $\text{Et}_2\text{O}$  (1 mL) and the resulting precipitate isolated by centrifugation at 5 °C (3200 rpm). The target compound was isolated by semipreparative HPLC (method A), the organic solvent removed by gentle rotary evaporation, and the resulting solution lyophilized overnight. The solid residue was desalted using SEC and a 100 mM  $\text{NH}_4\text{HCO}_3$  buffer, producing a colorless solid (1.5 mg, 74%) after lyophilization.  $^{19}\text{F}$  NMR (DMSO- $d_6$ ):  $\delta$  -109.60 (tt, 1F,  $J = 8.9, 5.6$  Hz); -109.58 (t,  $J = 8.9$  Hz). Anal. HPLC (method A):  $t_{\text{R}} = 9.15$  min. MS  $m/z$  ES(+): found, 1209.9 [M + 5H<sup>+</sup>]/5, 1512.1 [M + 4H<sup>+</sup>]/4, 2015.4 [M + 3H<sup>+</sup>]/3; calcd, 1209.6, 1511.7, 2015.3, respectively.

**Digestion Studies.** A total of 25  $\mu\text{L}$  of 0.4 M  $\text{NH}_4\text{HCO}_3$  (aq) was added to 250  $\mu\text{L}$  of **8a** (2.4 mg/mL) in PBS in a 1.5 mL conical vial and the mixture agitated gently. To this was added 5  $\mu\text{L}$  of 45 mM aqueous dithiothreitol and the mixture incubated for 15 min at 50 °C. After cooling to room temperature, 5  $\mu\text{L}$  of 100 mM aqueous iodoacetamide was added and the solution agitated periodically over 15 min. An aliquot (56  $\mu\text{L}$ ) was mixed with 28  $\mu\text{L}$  of 0.4 M  $\text{NH}_4\text{HCO}_3$  in 8 M aqueous urea and the analysis performed by LCMS (ES+) over 160 min.

The remaining solution from the dithiothreitol experiment was transferred to a glass vial. To this was added 2.5  $\mu\text{L}$  of endoproteinase-Glu-C in MilliQ water and the mixture incubated for 16 h at 37 °C. An aliquot (56  $\mu\text{L}$ ) was mixed with 28  $\mu\text{L}$  of 0.4 M  $\text{NH}_4\text{HCO}_3$  in 8 M aqueous urea. Analysis was performed by LCMS (ES+).

**Receptor Binding Assay.** A human embryonic kidney (HEK-293) cell line that has been stably transfected to express human insulin receptors was incubated in the presence of  $1.4 \times 10^{-10}$  M of  $^{125}\text{I}$ -insulin and varying concentrations of unlabeled human insulin or FB-AHx-insulin. Cells were incubated in 50 mM PBS with 0.5% BSA for 120 min at 4 °C and then washed three times. The pelleted cells were counted on a  $\gamma$ -counter and results were reported as percent binding (cpm sample/cpm added  $\times$  100).

For cellular autophosphorylation assays, CHO-hIR cells were grown in  $\alpha$ -MEM, 10% FBS with 10  $\mu\text{g}/\text{mL}$  gentamicin, serum deprived for 1 h, and then incubated with either human insulin (Aventis) or FB-AHx-insulin at the indicated concentrations for 10 min. Cells were then lysed in a buffer consisting of 50 mM HEPES, pH 7.4, 150 mM NaCl, 1% NP-40, 0.1% deoxycholate, 0.1% SDS, 1 mM  $\text{Na}_3\text{VO}_4$ , 0.1 mM EGTA, and 1 Roche EDTA-free Protease Inhibitor Cocktail Tablet (per 50 mL volume). Lysates were clarified by centrifugation at 100 000g for 5 min at 4 °C and applied to 96-well plates coated with anti-insulin receptor monoclonal antibodies (29B4 antibody). The extent of autophosphorylation was quantified using a second antibody directed against phosphotyrosine residues (HRP-conjugated PY20, Oncogene Research Products) and a coupled horseradish peroxidase reaction (ELISA). 2-Deoxyglucose uptake in 3T3-L1 adipocytes in response to human insulin or FB-AHx-insulin at the indicated concentrations was determined as previously described.<sup>30</sup>

**Radiosynthesis. B<sup>1</sup>-([4- $^{18}\text{F}$ -Fluorobenzoyl]-6-aminohexanoyl)-insulin ( $^{18}\text{F}$ B-AHx-insulin,  $^{18}\text{F}$ -8b).** To an anhydrous  $\text{CH}_3\text{CN}$  (500  $\mu\text{L}$ ) solution of  $^{18}\text{F}$ -fluoride containing 8 mg of  $\text{K}_{222}$  was added pentamethylbenzyl 4-(*N,N,N*-trimethylammonium trifluoromethanesulfonate)benzoate (**9**)<sup>28</sup> (3.0 mg, 6.13  $\mu\text{mol}$ ) dissolved in anhydrous  $\text{CH}_3\text{CN}$  (500  $\mu\text{L}$ ). The vial was capped tightly and placed in a heating block at 130 °C for 10 min with stirring. The reaction vessel was cooled using an ice-water bath and the activity measured. The resulting light yellow solution was diluted with  $\text{Et}_2\text{O}$  (3 mL) and passed through an activated silica cartridge collecting  $^{18}\text{F}$ -**10** in a 10-mL vial. The cartridge was washed with  $\text{Et}_2\text{O}$  (3 mL) and the activity combined with the initial eluent to give the desired product in 67–81% yield. Anal. HPLC (method C):  $t_{\text{R}} = 25.7$  min.  $\text{SiO}_2$ -TLC:  $\text{CH}_3\text{CN}/\text{H}_2\text{O}$  95/5 (v/v),  $R_f = 0.97$ .

The  $\text{Et}_2\text{O}$  solvent was removed by heating the solution to 90 °C while passing a gentle stream of nitrogen over the reaction vial for 4–6 min. The dried sample was subsequently placed in a water-ice bath, neat TFA (200  $\mu\text{L}$ ) added, and the mixture stirred for 5 min. The solution was diluted with  $\text{H}_2\text{O}$  (5 mL) and passed through an activated  $\text{C}_{18}$  cartridge. The cartridge was washed with  $\text{H}_2\text{O}$  (5 mL) and then dried for 1 min by applying a stream of nitrogen. 4- $^{18}\text{F}$ -Fluorobenzoic acid ( $^{18}\text{F}$ BA) ( $^{18}\text{F}$ -**11**) was eluted from the Sep-Pak using anhydrous  $\text{CH}_3\text{CN}$  (3 mL), which was collected in a 10-mL vial in 77–95% yield. Anal. HPLC (method C):  $t_{\text{R}} = 7.89$  min.  $\text{SiO}_2$ -TLC:  $\text{CH}_3\text{CN}/\text{H}_2\text{O}$  95/5 (v/v),  $R_f = 0.34$ .

1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (34 mg, 0.17 mmol) and *N*-hydroxysuccinimide (20 mg, 0.17 mmol) was added to **11** in anhydrous  $\text{CH}_3\text{CN}$  (500  $\mu\text{L}$ ). The reaction was stirred at room temperature for 10 min, whereupon it was concentrated to approximately a 0.5–1 mL volume by heating the solution at 90 °C for 6–8 min under a gentle stream of nitrogen. To this sample was added enough  $\text{H}_2\text{O}$  to make a total volume of 1.5 mL. The solution was purified by semipreparative HPLC (method D), collecting the peak corresponding to the succinimidyl 4- $^{18}\text{F}$ -fluorobenzoate (4- $^{18}\text{F}$ SB). The HPLC eluent was transferred to a 20-mL syringe containing 14 mL of  $\text{H}_2\text{O}$ , and the entire volume was passed through an activated  $\text{C}_{18}$  cartridge. After drying the cartridge under a stream of nitrogen (1 min), pure **2b** was collected (71–91% yield) in a 10-mL vial by flushing  $\text{CH}_3\text{CN}$  (3 mL) through the cartridge. Anal. HPLC (method C):  $t_{\text{R}} = 10.53$  min.  $\text{SiO}_2$ -TLC:  $\text{CH}_3\text{CN}/\text{H}_2\text{O}$  95/5 (v/v),  $R_f = 0.88$ .

The solution containing **2b** was concentrated to dryness at 90 °C under a slow stream of nitrogen (6–8 min). To the dried sample was added **6** (2 mg, 0.16  $\mu\text{mol}$ ) dissolved in DMSO (200  $\mu\text{L}$ ) containing 10% TEA (v/v). The reaction was allowed to stir at room temperature for 20 min and subsequently diluted with 100 mM  $\text{NH}_4\text{-HCO}_3$  (1 mL). The reaction mixture was loaded onto an activated SEC Sep-Pak, which was washed with 2 mL of 100 mM  $\text{NH}_4\text{-HCO}_3$ . The product was subsequently eluted using an additional 3 mL of 100 mM  $\text{NH}_4\text{HCO}_3$ , which was collected in a 10-mL vial. This fraction was loaded onto a  $\text{C}_{18}$  cartridge, which was washed with  $\text{H}_2\text{O}$  (5 mL) and dried for 1 min using a stream of nitrogen. The desired product was isolated in 32–53% yield by passing  $\text{CH}_3$ -

CN (3 mL) containing 0.1% TFA (v/v) through the cartridge. Anal. HPLC (method C):  $t_{\text{R}} = 12.1$  min.

The  $\text{CH}_3\text{CN}$  solution of **7b** was concentrated to dryness by passing a stream of nitrogen over the sample, which was heated to 30 °C for approximately 15–20 min. TFA (400  $\mu\text{L}$ ) containing 5% anisole (v/v) was then added and the mixture allowed to stir for 5 min, at which time, the TFA was removed under a stream of nitrogen (2–3 min). The residue was redissolved in  $\text{EtOH}$  (200  $\mu\text{L}$ ) and 50/50  $\text{NaCl}/\text{Na}_2\text{HPO}_4$  (800  $\mu\text{L}$ , 0.9%, USP grade). The mixture was transferred to an activated SEC cartridge, which was eluted with 2 mL 50/50  $\text{NaCl}/\text{Na}_2\text{HPO}_4$  (0.9%, USP grade), and the 3 mL of buffer was collected in one vial. The solution containing **8b** (31–77% yield) was filtered through a Millipore frit prior to use. Anal. HPLC (method C):  $t_{\text{R}} = 10.7$  min.

**Acknowledgment.** The authors would like to thank Xiuling Guo, Deborah Finco-Kent, Stephen J. Orena and Anne M. Brodeur for performing the biological assays, Pfizer Inc. and the Ontario Research and Development Fund (ORDCF) for their financial support of this work, and the Ministry of Human Resources, Training and Universities of Ontario for an Ontario Graduate Scholarship for K.J.G. We would also like to acknowledge the Department of Nuclear Medicine, Hamilton Health Sciences, for providing  $^{18}\text{F}$  and access to radiochemistry facilities.

**Supporting Information Available:** HPLC data and NMR spectra. This material is available free of charge via the Internet at <http://pubs.acs.org>.

## References

- (1) Doubrovin, M.; Serganova, I.; Mayer-Kuckuk, P.; Ponomarev, V.; Blasberg, R. G. Multimodality in Vivo Molecular-Genetic Imaging. *Bioconjugate Chem.* **2004**, *15*, 1376–1388.
- (2) Cherry, S. R. In Vivo Molecular and Genomic Imaging: New Challenges for Imaging Physics. *Phys. Med. Biol.* **2004**, *49*, R13–R48.
- (3) Saltiel, A. R.; Kahn, C. R. Insulin Signalling and the Regulation of Glucose and Lipid Metabolism. *Nature* **2001**, *414*, 799–806.
- (4) DeFronzo, R. A. Insulin Resistance: A Multifaceted Syndrome Responsible for NIDDM, Obesity, Hypertension, Dyslipidaemia and Atherosclerosis. *Neth. J. Med.* **1997**, *50*, 191–197.
- (5) Stratton, I. M.; Adler, A. I.; Neil, H. A. W.; Matthews, D. R.; Manley, S. E.; Cull, C. A.; Hadden, D.; Turner, R.; Holman, R. R. Association of Glycaemia With Macrovascular and Microvascular Complications of Type 2 Diabetes (UKPDS 35): Prospective Observational Study. *Br. Med. J.* **2000**, *321*, 405–412.
- (6) DCCT: The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus. *New Engl. J. Med.* **1993**, *329*, 977–986.
- (7) Paternostro, G.; Pagano, D.; Gneccchi-Ruscione, T.; Bonser, R. S.; Camici, P. G. Insulin Resistance in Patients with Cardiac Hypertrophy. *Cardiovascular Res.* **1999**, *42*, 246–253.
- (8) Hoyer, S. Is sporadic Alzheimer Disease the Brain Type of Non-Insulin Dependent Diabetes Mellitus? A Challenging Hypothesis. *J. Neural Transm.* **1998**, *105*, 415–422.
- (9) Kaaks, R.; Toniolo, P.; Akhmedkhanov, A.; Lukanova, A.; Biessy, C.; Dechaud, H.; Rinaldi, S.; Zeleniuch-Jacquotte, A.; Shore, R. E.; Riboli, E. Serum C-Peptide, Insulin-like Growth Factor (IGF)-I, IGF-Binding Proteins and Colorectal Cancer Risk in Women. *J. Natl. Cancer Inst.* **2000**, *92*, 1592–1600.
- (10) Sodoyez, J. C.; Sodoyez-Goffaux, F.; Goff, M. M.; Zimmerman, A. E.; Arquilla, E. R. Preparation, Physical, Immunological and Biological Properties and Susceptibility to “Insulinase” Degradation. *J. Biol. Chem.* **1975**, *250*, 4268–4277.
- (11) Wajchenberg, B. L.; Pinto, H.; de Toledo e Souza, I. T.; Lerário, A. C.; Pieroni, R. R. Preparation of Iodine-125-Labeled Insulin for Radioimmunoassay: Comparison of Lactoperoxidase and Chloramine-T Iodination. *J. Nucl. Med.* **1978**, *19*, 900–905.
- (12) Jørgensen, K. H.; Larsen, U. D. Homogeneous Mono-[125I]-Insulins: Preparation and Characterization of Mono-[125I]-(Tyr A14)- and Mono-[125I]-(Tyr A19)-Insulin. *Diabetologia* **1980**, *19*, 546–554.
- (13) Rissler, K.; Engelmann, P. Labeling of Insulin with Non-Radioactive 125I and Application to Incorporation of Radioactive 125I for Use in Receptor-Binding Experiments by High-Performance Liquid Chromatography. *J. Chromatogr. B—Biomed. Appl.* **1996**, *679*, 21–29.



- (14) Owens, D. R.; Coates, P. A.; Luzio, S. D.; Tinbergen, J. P.; Kurzhals, R. Pharmacokinetics of 125I-Labeled Insulin Glargine (HOE 901) in Healthy Men: Comparison With NPH Insulin and the Influence of Different Subcutaneous Injection Sites. *Diabetes Care* **2000**, *23*, 813–819.
- (15) Shai, Y.; Kirk, K. L.; Channing, M. A.; Dunn, B. B.; Lesniak, M. A.; Eastman, R. C.; Finn, R. D.; Roth, J.; Jacobson, K. A. 18F-Labeled Insulin: A Prosthetic Group Methodology for Incorporation of a Positron Emitter into Peptides and Proteins. *Biochemistry* **1989**, *28*, 4801–4806.
- (16) Eastman, R. C.; Carson, R. E.; Jacobson, K. A.; Shai, Y.; Channing, M. A.; Dunn, B. B.; Bacher, J. D.; Baas, E.; Jones, E.; Kirk, K. L.; Lesniak, M. A.; Roth, J. In Vivo Imaging of Insulin Receptors in Monkeys Using 18F-Labeled Insulin and Positron Emission Tomography. *Diabetes* **1992**, *41*, 855–860.
- (17) Glaser, M.; Brown, D. J.; Law, M. P.; Iozzo, P.; Waters, S. L.; Poole, K.; Knickmeier, M.; Camici, P. G.; Pike, V. W. Preparation of No-Carrier-Added [124I]A<sub>14</sub>-Iodoinsulin as a Radiotracer for Positron Emission Tomography. *J. Labelled Compd. Radiopharm.* **2001**, *44*, 465–480.
- (18) Iozzo, P.; Osman, S.; Glaser, M.; Knickmeier, M.; Ferrannini, E.; Pike, V. W.; Camici, P. G.; Law, M. P. In Vivo Imaging of Insulin Receptors by PET: Preclinical Evaluation of Iodine-125 and Iodine-124 Labelled Human Insulin. *Nucl. Med. Biol.* **2002**, *29*, 73–82.
- (19) Pullen, R. A.; Lindsay, D. G.; Wood, S. P.; Tickle, I. J.; Blundell, T. L.; Wollmer, A.; Krail, G.; Brandenburg, D.; Zahn, H.; Gliemann, J.; Gammeltoft, S. Receptor-Binding Region of Insulin. *Nature* **1976**, *259*, 369–373.
- (20) Gliemann, J.; Gammeltoft, S. The Biological Activity and the Binding Affinity of Modified Insulins Determined on Isolated Rat Fat Cells. *Diabetologia* **1974**, *10*, 105–113.
- (21) Hashimoto, M.; Takada, K.; Kiso, Y.; Muranishi, S. Synthesis of Palmitoyl Derivatives of Insulin and Their Biological Activities. *Pharm. Res.* **1989**, *6*, 171–176.
- (22) Murray-Rust, J.; McLeod, A. N.; Blundell, T. L.; Wood, S. P. Structure and Evolution of Insulins: Implications for Receptor Binding. *BioEssays* **1992**, *14*, 325–331.
- (23) Blundell, T. L.; Dodson, G. G.; Hodgkin, D. C.; Mercola, D. Insulin: The Structure in the Crystal and Its Reflection in Chemistry and Biology. *Adv. Protein Chem.* **1972**, *26*, 279–402.
- (24) Baudyš, M.; Uchio, T.; Mix, D.; Wilson, D.; Kim, S. W. Physical Stabilization of Insulin by Glycosylation. *J. Pharm. Sci.* **1995**, *84*, 28–33.
- (25) Lundt, B. F.; Johansen, N. L.; Voelund, A.; Markussen, J. Removal of *tert*-Butyl and *t*-Butoxycarbonyl Protecting Groups with Trifluoroacetic Acid. Mechanisms, Byproduct Formation and Evaluation of Scavengers. *Int. J. Pept. Protein Res.* **1978**, *12*, 258–268.
- (26) Weiss, M. A.; Nguyen, D. T.; Khait, I.; Inouye, K.; Frank, B. H.; Beckage, M.; O'Shea, E.; Shoelson, S. E.; Karplus, M.; Neuringer, L. J. Two-Dimensional NMR and Photo-CIDNP Studies of the Insulin Monomer: Assignment of Aromatic Resonances with Application to Protein Folding, Structure, and Dynamics. *Biochemistry* **1989**, *28*, 9855–9873.
- (27) Matsudaira, P. T. *A Practical Guide to Protein and Peptide Purification for Microsequencing*; 2nd ed.; Academic Press: San Diego, CA, 1993; pp 55–59.
- (28) Lang, L.; Jagoda, E. M.; Schmall, B.; Vuong, B.-K.; Adams, R. H.; Nelson, D. L.; Carlson, R. E.; Eckelman, W. C. Development of Fluorine-18-Labeled 5-HT<sub>1A</sub> Antagonists. *J. Med. Chem.* **1999**, *42*, 1576–1586.
- (29) Fredriksson, A.; Johnström, P.; Stone-Elander, S.; Jonasson, P.; Nygren, P.-Å.; Ekberg, K.; Johansson, B.-L.; Wahren, J. Labeling of Human C-Peptide by Conjugation With N-Succinimidyl-4-[18F]-fluorobenzoate. *J. Labelled Compd. Radiopharm.* **2001**, *44*, 509–519.
- (30) Orena, S. J.; Torchia, A. J.; Garofalo, R. S. Inhibition of Glycogen Synthase Kinase-3 Stimulates Glycogen Synthase and Glucose Transport by Distinct Mechanisms in 3T3-L1 Adipocytes. *J. Biol. Chem.* **2000**, *275*, 15765–15772.

JM0509344